Latin America Anti Diabetic Biosimilars Market By Drug Class (Insulin, Biguanides, Sulfonyl Ureas, Thiazolidinediones, Di Peptidyl Peptidase (DPP)-IV Inhibitors, ?-glucosidase Inhibitos, GLP-1 Agonists, SGLT-2 Inhibitors, Others), By Disease Type (Type-I Diabetes, Type-II Diabetes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)and Geography  

Purchase Option

$ 3000
$ 4400
$ 4600
$ 6900

Latin America Anti diabetic Biosimilars Market size was estimated at USD X Bn in 2022, growing at a CAGR of X% during the forecast period 2022-2028. Biosimilars are biological substances that are highly similar to biologics but not identical with patented biological molecules. These are manufactured after the patent expiration of original products. Anti-diabetic biosimilars are help to control the blood glucose levels in the diabetic patients. Commonly used anti-diabetic drugs include biguanides, sulfonyl ureas, GLP-1 receptor agonists, DPP-IV inhibitors, thiazolidinediones, and insulin among others. These are cost-effective molecules with similar potency and efficiency compared with reference biologic molecules. Drivers are Increase in the prevalence of diabetes, Patent expiries of block buster drugs and promising product pipeline and Expansion of business by the market players. Restraints are High cost and longer duration of R&D activities, Stringent regulatory policies and Complexity in development of biosimilars. Our continuous study is enhancing our research approach to guarantee that fundamental COVID-19 concerns and potential solutions are included. The research examines COVID-19 in light of changes in consumer behaviour and demand, purchasing patterns, supply chain re-routing, market dynamics, and government involvement. Latin America Anti diabetic Biosimilars Market Research Report considers the influence of COVID-19 on the market and includes insights, analysis, projections, and predictions.

Latin America Anti Diabetic Biosimilars Market Summary

Study Period


Base Year




Largest Market


Fastest Growing Market

Latin America Anti diabetic Biosimilars Market Dynamics Drivers And Restraints

The rising prevalence of diabetes, the difficulties of alternative diabetic medications, and government incentives for the introduction of low-cost medicines are all contributing to the market's rise. 

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Latin America Anti Diabetic Biosimilars Market Segmentation

drug class
  • Insulin
  • Biguanides
  • Sulfonyl Ureas
  • Thiazolidinediones
  • Di Peptidyl Peptidase (DPP)-IV Inhibitors
  • ?-glucosidase Inhibitos
  • GLP-1 Agonists
  • Others
disease type
  • Type-I Diabetes
  • Type-II Diabetes
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Brazil
  • Mexico
  • Argentina
  • Venezuela
  • Rest of Latin America

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

[urltag url='request-table-of-content']

  • Merck Sharp & Dohme Corporation (U.S.)
  • Boehringer Ingelheim GmbH (Germany)
  • Eli Lilly & Co. (U.S.)
  • Sanofi-aventis U.S. LLC (U.S.)
  • Samsung Bioepis (Samsung BioLogics) (South Korea)
  • Mylan N.V. (U.S.)
  • Wockhardt (India)